DAY301 | Day One Biopharmaceuticals
Emi‑Le is an investigational product that has demonstrated early anti‑tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma (ACC).
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features
- A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug
- Deciphering the potential pathogeny of rare tracheal adenoid cystic carcinoma by single‑cell RNA‑sequencing
- Adenoid cystic carcinoma (ACC)
- Completed Studies – Adenoid Cystic Carcinoma Research Foundation